Abstract:Background: Acute lung injury caused by renal ischemia-reperfusion is one of the leading causes of acute kidney injury-related death. Dexmedetomidine, an alpha(2)-adrenergic agonist sedative, has been found to have protective effects against acute kidney injury and remote lung injury. We sought to determine whether dexmedetomidine can exert its anti-apoptotic effects in acute lung injury after acute kidney injury, in addition to its common anti-inflammatory effects, and to determine the underlying mechanisms.Methods: In vivo, acute kidney injury was induced by 60 min of kidney ischemia (bilateral occlusion of renal pedicles) followed by 24 h of reperfusion. Mice received dexmedetomidine (25 mu g/kg, i.p.) in the absence or presence of alpha(2)-adrenergic antagonist atipamezole (250 mu g/kg, i.p.) before IR. Histological assessment of the lung was conducted by HE staining and arterial blood gases were measured. Lung apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay. The expression of caspase 3 and p-Akt in lung tissue was detected by western blot. In vitro, C57BL/6J mice pulmonary microvascular endothelial cells were treated with serum from mice obtained following sham or IR. Dexmedetomidine was given before serum stimulation in cells, alone or with atipamezole or LY294002. Cell viability was assessed by CCK 8 assay. Cell apoptosis was examined by Hoechst staining and Annexin V-FITC/PI staining flow cytometry analysis. Mitochondrial membrane potential was measured by flow cytometry. The expression of p-Akt, caspase 3, Bcl-2 and Bax was measured by western blot.Results: In vivo, dexmedetomidine remarkably mitigated pathohistological changes and apoptosis and significantly increased p-Akt expression in the lung. In addition, dexmedetomidine also slightly improved oxygenation in mice after IR, which can be abolished by atipamezole. In vitro, dexmedetomidine significantly inhibited IR serum-induced loss of viability and apoptosis in PMVECs. Dexmedetomidine increased p-Akt in a time-and dose-dependent manner, and down-regulated the expression of caspase 3 and Bax and up-regulated the Bcl-2 expression in PMVECs. The changes of MMP were also improved by dexmedetomidine. Whilst these effects were abolished by Atipamezole or LY294002.Conclusion: Our results demonstrated that dexmedetomidine attenuates lung apoptosis induced by IR, at least in part, via alpha(2)AR/PI3K/Akt pathway.

Protective Effect of Dexmedetomidine on Acute Lung Injury via the Upregulation of Tumour Necrosis Factor-α-Induced Protein-8-like 2 in Septic Mice

Dexmedetomidine Attenuates Inflammatory Reaction in the Lung Tissues of Septic Mice by Activating Cholinergic Anti-Inflammatory Pathway

Dexmedetomidine Attenuates Oxidative/nitrative Stress in Lung Tissues of Septic Mice Partly Via Activating Heme Oxygenase-1.

Effect of Dexmedetomidine on JAK2/STAT3 Signaling Pathway in Mice with Endotoxin-Induced Acute Lung Injury

Dexmedetomidine attenuates sepsis-associated acute lung injury by regulating macrophage efferocytosis through the ROS/ADAM10/AXL pathway

TIPE2 ameliorates lipopolysaccharide-induced apoptosis and inflammation in acute lung injury

Role of TIPE2 in endogenous protective mechanism of acute lung injury in septic mice: the relationship with TAK1/p38 MAPK/NF-κB signaling pathway

The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways.

The Protective Effect of Dexmedetomidine on LPS-induced Acute Lung Injury Through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR Pathways

Dexmedetomidine Alleviates Blunt Chest Trauma and Hemorrhagic Shock‑resuscitation‑induced Acute Lung Injury Through Inhibiting the NLRP3 Inflammasome.

Dexmedetomidine Activates Akt, STAT6 and IRF4 Modulating Cytoprotection and Macrophage Anti-Inflammatory Phenotype Against Acute Lung Injury in Vivo and in Vitro

Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway

Dexmedetomidine alleviates cognitive impairment by reducing blood-brain barrier interruption and neuroinflammation via regulating Th1/Th2/Th17 polarization in an experimental sepsis model of mice

Dexmedetomidine Ameliorates LPS Induced Acute Lung Injury Via GSK-3β/STAT3-NF-κB Signaling Pathway in Rats

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Sympathetic Activation and Sepsis via Suppressing Superoxide Signaling in Paraventricular Nucleus

Dexmedetomidine Attenuates Lung Apoptosis Induced By Renal Ischemiareperfusion Injury Through Alpha(2)Ar/Pi3k/Akt Pathway

The Α2ar/caveolin‐1/p38mapk/nf‐κb Axis Explains Dexmedetomidine Protection Against Lung Injury Following Intestinal Ischaemia‐reperfusion

Dexmedetomidine Attenuates Lipopolysaccharide-Induced Liver Oxidative Stress and Cell Apoptosis in Rats by Increasing GSK-3β/MKP-1/Nrf2 Pathway Activity Via the Α2 Adrenergic Receptor.

Dexmedetomidine attenuates lung apoptosis induced by renal ischemia–reperfusion injury through α 2 AR/PI3K/Akt pathway

The protective effect of dexmedetomidine on the liver injury in sepsis through inhibition of necroptosis

Effects of Dexmedetomidine on Early and Late Cytokines During Polymicrobial Sepsis in Mice